Immunoproteasome subunit LMP2 expression is deregulated in Sjögren’s syndrome but not in other autoimmune disorders

Background: The proteasome system has a pivotal role in the control of the immune response, which suggests that it might be involved in the pathogenesis of autoimmune disorders. Objective: To investigate the expression profile of selected proteasomal genes in human peripheral blood mononuclear cells...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 65; no. 8; pp. 1021 - 1027
Main Authors Krause, S, Kuckelkorn, U, Dörner, T, Burmester, G-R, Feist, E, Kloetzel, P-M
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and European League Against Rheumatism 01.08.2006
Elsevier Limited
BMJ Group
Subjects
Online AccessGet full text
ISSN0003-4967
1468-2060
DOI10.1136/ard.2005.045930

Cover

More Information
Summary:Background: The proteasome system has a pivotal role in the control of the immune response, which suggests that it might be involved in the pathogenesis of autoimmune disorders. Objective: To investigate the expression profile of selected proteasomal genes in human peripheral blood mononuclear cells in patients with a variety of autoimmune diseases compared with healthy subjects. Methods: Real time quantitative RT-PCR was used to analyse the mRNA expression pattern of the proteasome activator subunits PA28α and PA28β and of constitutive proteasome and interferon-γ-inducible immunoproteasome subunits in peripheral blood mononuclear cells. Simultaneously, protein expression of selected proteasome subunits was quantified by immunoblotting. Results: Under systemic inflammatory conditions the proteasome subunits LMP2 (β1i), LMP7 (β5i), MECL1 (β2i), and PA28α were expressed abundantly at the protein level in the vast majority of systemic autoimmune disorders. However, simultaneous mRNA and protein quantification showed a characteristic proteasome expression signature in primary Sjögren’s syndrome. At the transcript level, the interferon-γ-responsive subunits LMP2 (β1i), MECL1 (β2i), and the proteasome activator subunit PA28α were markedly up regulated. In contrast, LMP2 (β1i) deficiency was evident at the protein level, indicating deregulation of proteasome expression in Sjögren’s syndrome. Conclusions: These data provide evidence for a regulatory defect in the proteasome system in human autoimmune disorders, pointing to a unique role for LMP2 (β1i) in the pathogenesis of primary Sjögren’s syndrome.
Bibliography:ark:/67375/NVC-QKNG3GMW-N
PMID:16414974
href:annrheumdis-65-1021.pdf
Correspondence to:
 Dr S Krause
 Friedrich-Baur-Institute, Laboratory of Molecular Myology, Department of Neurology, Ludwig-Maximilians University, Marchioninistr 17, 81377 Munich, Germany; sabine.krause@med.uni-muenchen.de
istex:DCFDF4E681BACEC99DBEA3FF3F62EBFD95BC40FB
local:0651021
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Copyright © 2006 BMJ Publishing Group Ltd & European League Against Rheumatism
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.2005.045930